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Multiplex diagnostic testing refers to the use of labora-
tory devices that perform many assays on the same 
specimen at the same time with a single laboratory plat-
form. In some respects, autoimmune rheumatic disease 
tests have long involved multiplexing. For example, the 
immunoﬂ   uorescence test for antibodies to nuclear 
antigens (ANAs) detects multiple ANA patterns and 
speciﬁ   cities. Modern multiplex methodology typically 
involves suspensions of antigen-coated microscopic 
beads that are distinguishable by physical characteristics 
such as ﬂ  uorescent color. Research multiplex assays may 
employ planar arrays of antigens spotted on glass slides. 
Panels of automated multiplex clinical laboratory tests 
are available for autoantibody testing, such as testing for 
the speciﬁ  cities of ANAs. Multiplex research assays are 
widely used to test for cytokines and other biomarkers. In 
a recent issue of Arthritis Research & Th  erapy, Chandra 
and colleagues [1] explored the use of multiple multiplex 
assays (a ‘megaplex’?) in the evaluation and categorization 
of patients with rheumatoid arthritis (RA).
Implementing high-quality multiplexed protein assays 
has many technical analytical challenges, including 
problems of uniformity, cross-reactivity, and optimiza-
tion [2,3]. Rheumatoid factors and other anti-reagent 
antibodies may interfere [4], as, indeed, they can interfere 
with individual immunoassays. Ideally, each individual 
assay included in the multiplex assay should be evaluated 
fully. Other criteria for evaluating reports of multiplex 
assays are suggested in Table 1.
How should multiplex laboratory data be interpreted? 
When the biomarker number is small and their clinical 
value is understood, results can be sent to the provider 
directly for interpretation. However, access to multiple test 
results supports the creation of predictors that are more 
complex and hopefully more accurate, since they are based 
on the integrated results from more parameters.
Diagnostic algorithms using multiple biomarkers and 
complex multivariate data analysis have been investigated 
the most in oncology. Some oncolo  gists express concern 
about a pattern of false discoveries in this ﬁ  eld  [5,6]. 
Some of the concerns raised by the oncology studies are 
relevant to rheumatology. One important message is that 
diﬀ  erences in the ‘pre-ana  lytical’ phase of testing (that is, 
factors such as phlebo  tomy conditions and storage) can 
cause diﬀ  erences in laboratory test results, which may be 
magniﬁ   ed and masked by complex computations, and 
lead to incorrect conclusions. Measurement of some 
cytokines, hormones, and other biomarkers is known to 
be inﬂ   uenced by specimen handling [5,7]. In some 
ovarian cancer studies, initially exciting ﬁ  ndings  were 
determined to be caused not by the diagnosis but by 
diﬀ  erent specimen handling by the institutions where the 
specimens originated [8]. What this points out is the 
importance of uniform specimen handling. It has been 
proposed that biomarker discovery and evaluation rely 
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In a recent issue of Arthritis Research & Therapy, 
Chandra and colleagues described the use of multiple 
multiplex immunoassays and complex computer 
algorithms to investigate the possibility of improved 
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rheumatoid arthritis on the basis of biomarkers. 
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of uniform specimen handling and prospectively 
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include the range of subjects likely to be tested clinically, 
followed by blinded retro  spective laboratory testing of 
sera from patients and controls randomly selected from 
the original prospective cohort. Th  is so-called PRoBE 
(prospective specimen collection, blinded evaluation 
retrospectively) approach strengthens biomarker 
discovery and validation [9]. Establishing multipurpose 
population-based repositories may be necessary for 
deﬁ  nitive biomarker studies.
Many of the hopes and challenges of computer-assisted 
multiplex laboratory diagnostics are demonstrated in the 
paper by Chandra and colleagues. Th  e authors used 7 
diﬀ  erent arrays to measure 41 conventional and novel 
autoantibodies and biomarkers. In addition, the authors 
used a multiplex bead assay to measure 13 selected cyto-
kines and chemokines. Sera from 120 patients with RA, 
55 rheumatic disease control patients, and 25 healthy 
individuals were tested. Over 1,100 RA sera were used to 
compare the analytical performance of novel and conven-
tional immunoassays for rheumatoid factor and C-
reactive protein, and precision data were provided for 4 
biomarkers.
Th   e studies have the potential to be confounded by the 
demographic and pre-analytic specimen handling issues 
described previously: the sera from patients with RA 
came from one repository, the sera from spondylitis and 
psoriatic arthritis control patients each came from 
diﬀ  erent sites, and the normal control sera were from 
another site. Diﬀ  erences between prolactin concen  tra-
tions in diﬀ  erent diagnostic groups were observed in this 
study, as in some previous ovarian cancer populations in 
which serum prolactin diﬀ   erences were explained by 
diﬀ  erences in specimen handling.
Th  e computerized cluster analysis in the paper by 
Chandra and colleagues suggested that RA patients could 
be subdivided by distinct biomarker proﬁ  les.  Th  e US 
Food and Drug Administration (FDA) has used the term 
‘in vitro diagnostic multivariate index assay’ (IVDMIA) to 
describe laboratory assays that combine the values of 
multiple individual tests into a single result or index that 
is not transparent and cannot be easily veriﬁ  ed by the 
provider [10], and the cluster analysis by the authors ﬁ  ts 
into that category. Although the FDA has yet to produce 
deﬁ  nitive guidelines for the evaluation of IVDMIAs, the 
suggestion is that tests of high complexity with high 
stakes for diagnosis or treatment (or both) will require 
proof of eﬃ   cacy before being approved for clinical use. 
Some suggested criteria for evaluating reports of 
IVDMIAs are included in Table 2. One of the suggested 
criteria, which is common to all multivariate approaches, 
is that the ratio of cases of interest used to generate the 
model should be high relative to the number of predictor 
variables (a ratio of 10:1 to 20:1 has been suggested as a 
general rule) in order to have conﬁ  dence in the results [11].
In the end, did the measurement of 54 biomarkers by 
Chandra and colleagues lead to improved diagnostic per-
for  mance? From the 54 initial biomarkers, combinations 
of 6 tests (including 3 anti-citrullinated peptide assays) 
had the best diagnostic discrimination. However, the 
combinations performed no better than anti-CCP (anti-
cyclic citrullinated protein antibodies) alone.
Where is rheumatology laboratory testing in the search 
for multiplex and multivariate approaches to diagnosis 
and stratiﬁ  cation? Multiplex testing for ANA and ANCA 
(anti-neutrophil cytoplasmic antibodies) speciﬁ  cities  is 
expanding. Multivariate assay approaches for lupus, RA, 
and other rheumatic diseases are being investigated. 
Whether or not these multivariate approaches lead to 
clinically signiﬁ  cant and cost-eﬀ  ective improvement in 
testing remains to be seen, but, appropriately, the search 
is on. Chandra and colleagues are to be congratulated for 
their exploratory studies.
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Table 1. Criteria for evaluating multiplex assays
1.  Analytical performance parameters (for example, precision, analytical 
sensitivity, and linearity) of assays should be available for each analyte.
2.  The clinical performance (clinical sensitivity and specifi  city) of each 
analyte within the multiplex should be comparable to that of assays for 
individual analytes.
3.  The time required to produce all results of multiplex assay should be less 
than the sum of time required to produce results of individual assays.
4.  The combination of multiplex assays should be appropriate for 
answering clinical questions; that is, the combinations of analytes 
measured within multiplex assay should make clinical sense.
Table 2. Criteria for evaluating multivariate index assays
1.  Normal control and disease control groups used to generate the index 
should be matched demographically (age, gender, race, and geography) 
with the target group.
2.  Pre-analytical variables (specimen type, specimen handling, and 
specimen storage) should be equivalent in control and diseased groups.
3.  There should be a high ratio of subjects (patients) to measured analytes 
used to generate the index.
4.  The accuracy (clinical sensitivity and specifi  city) of the index test should 
be tested and reported on the basis of populations of subjects (the ‘test 
set’ of diseased patients and controls) independently of the subjects (the 
‘training set’) used to generate the index formulae or calculations.
5.  The clinical accuracy (clinical sensitivity and specifi  city) of the index 
test should be compared with the accuracy of the most accurate of the 
individual analytes within the index or with the best available single 
diagnostic laboratory test or both.
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